Table 2.
Treatments and cells analyzed | Totala | Comet class |
Scores | Reduction (%)b | |||
---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | ||||
Peripheral blood (4 h sample) | |||||||
6,7-HC 25 mg kg−1+ DXR 80 mg kg−1 | 13.00 ± 2.38* | 87.00 ± 2.38 | 11.50 ± 1.71 | 1.50 ± 0.76 | 0.00 ± 0.00 | 14.50 ± 3.10* | 80.91 |
6,7-HC 50 mg kg−1 + DXR 80 mg kg−1 | 28.17 ± 3.24 | 71.83 ± 3.24 | 22.67 ± 2.49 | 5.00 ± 0.58 | 0.50 ± 0.50 | 34.17 ± 4.49 | 9.87 |
6,7-HC 500 mg kg−1 + DXR 80 mg kg−1 | 28.33 ± 3.50 | 71.67 ± 3.50 | 22.67 ± 2.49 | 5.17 ± 0.69 | 0.50 ± 0.50 | 34.50 ± 4.99 | 9.12 |
Doxorubicin (DXR) 80 mg kg−1 | 30.00 ± 3.42 | 72.17 ± 6.94 | 23.83 ± 2.54 | 5.00 ± 1.15 | 1.17 ± 0.37 | 37.33 ± 4.64 | |
Peripheral blood (24 h sample) | |||||||
6,7-HC 25 mg kg−1+ DXR 80 mg kg−1 | 18.17 ± 2.85* | 81.83 ± 2.85 | 15.33 ± 2.21 | 2.17 ± 0.69 | 0.67 ± 0.47 | 21.67 ± 3.99* | 85.63 |
6,7-HC 50 mg kg−1 + DXR 80 mg kg−1 | 34.17 ± 2.54 | 65.83 ± 2.54 | 29.00 ± 2.00 | 4.00 ± 0.82 | 1.17 ± 0.37 | 40.50 ± 3.30 | 27.11 |
6,7-HC 500 mg kg−1 + DXR 80 mg kg−1 | 32.67 ± 2.43 | 67.33 ± 2.43 | 27.00 ±1.29 | 4.00 ± 1.00 | 1.67 ± 0.75 | 40.00 ± 4.73 | 29.13 |
Doxorubicin (DXR) 80 mg kg−1 | 36.00 ± 4.43 | 64.00 ± 4.43 | 25.50 ± 6.24 | 8.50 ± 1.71 | 2.00 ± 0.82 | 48.50 ± 3.59 | |
Liver | |||||||
6,7-HC 25 mg kg−1+ DXR 80 mg kg−1 | 88.33 ± 1.34 | 11.17 ± 1.34 | 47.33 ± 2.75 | 29.33 ± 1.25 | 12.17 ± 0.69 | 142.50 ± 1.98 | 5.09 |
6,7-HC 50 mg kg−1 + DXR 80 mg kg−1 | 88.67 ± 2.43 | 11.33 ± 2.43 | 47.17 ± 2.41 | 29.33 ± 2.49 | 12.17 ± 2.91 | 142.33 ± 3.59 | 5.38 |
6,7-HC 500 mg kg−1 + DXR 80 mg kg−1 | 89.67 ± 1.89 | 10.33 ± 1.89 | 50.17 ± 1.95 | 27.33 ± 1.60 | 12.17 ± 1.77 | 141.33 ± 6.47 | 6.40 |
Doxorubicin (DXR) 80 mg kg−1 | 88.67 ± 3.14 | 11.33 ± 3.14 | 44.83 ± 2.03 | 30.33 ± 1.97 | 13.50 ± 1.38 | 149.00 ± 7.19 | |
Bone marrow | |||||||
6,7-HC 25 mg kg−1+ DXR 80 mg kg−1 | 87.67 ± 1.37 | 12.33 ± 1.37 | 39.17 ± 3.53 | 42.50 ± 1.89 | 6.00 ± 0.82 | 142.17 ± 2.41 | 8.07 |
6,7-HC 50 mg kg−1 + DXR 80 mg kg−1 | 90.83 ± 1.34 | 9.17 ± 1.34 | 35.83 ± 1.86 | 47.17 ± 1.77 | 7.83 ± 0.69 | 153.67 ± 2.21 | 0.12 |
6,7-HC 500 mg kg−1 + DXR 80 mg kg−1 | 88.67 ± 1.60 | 10.83 ± 1.77 | 35.17 ± 2.67 | 45.50 ± 2.43 | 8.00 ± 1.29 | 150.17 ± 3.48 | 2.36 |
Doxorubicin (DXR) 80 mg kg−1 | 90.67 ± 0.94 | 9.33 ± 0.94 | 35.00 ± 1.73 | 48.50 ± 1.71 | 7.17 ± 1.07 | 153.50 ± 1.98 | |
Testicular | |||||||
6,7-HC 25 mg kg−1+ DXR 80 mg kg−1 | 11.67 ± 2.81* | 88.33 ± 2.81 | 10.50 ± 2.22 | 1.17 ± 0.69 | 0.00 ± 0.00 | 12.83 ± 3.44* | 87.50 |
6,7-HC 50 mg kg−1 + DXR 80 mg kg−1 | 37.33 ± 2.43 | 62.67 ± 2.43 | 28.83 ± 1.77 | 6.00 ± 1.29 | 2.50 ± 0.50 | 48.33 ± 3.90 | 14.60 |
6,7-HC 500 mg kg−1 + DXR 80 mg kg−1 | 39.50 ± 5.19 | 60.50 ± 5.19 | 29.50 ± 2.36 | 7.83 ± 2.27 | 2.17 ± 0.69 | 51.67 ± 8.77 | 7.58 |
Doxorubicin (DXR) 80 mg kg−1 | 40.83 ± 4.56 | 60.83 ± 4.18 | 29.33 ± 2.56 | 9.00 ± 1.53 | 2.50 ± 0.76 | 54.83 ± 7.43 |
Significantly different from doxorubicin (P < 0.05).
Total number of damaged cells (class 1 + 2 + 3).
How much 6,7-HC decreased the genotoxicity of the DXR, according to Waters et al. [34].